Eli Lilly and Company

National Institutes of Health, a Component of the US Dept. of Health & Human Services

Emisphere Technologies, Inc.

Abcellera Biologies Inc.

Indiana University

Sorrento Therapeutics, Inc.

Abcellera Biologics Inc.

Bryan Edward Jones

Jeffry Dean Watkins

Brian W Grinnell

Barney S Graham

Ying Tang

David Matthew Marquis

Julian Davies

John Mascola

Lingshu Wang

Qing Chai

Kizzmekia S Corbett

Bruce Edward Gerlitz

Julie Ledgerwood

Jeffrey Streetman Boyles

Andrew Ihor Korytko

Gunnar F Kaufmann

Craig Duane Dickinson

Christopher Carl Frye

Wei Shi

Stefanie Zentelis

Anna Pustilnik

Kathryn Westendorf

Krithika Muthuraman

Kevin Jepson

Ester Falconer

Olubukola Abiona

Wing-pui Kong

Yi Zhang

Denisa Foster

Ganapathy Gopalrathnam

Jörg Hendle

John Michael Sauder

James David Pancook

Pamela Jean Mitchell

Rong Wang

John McNeil McGill

Scott William Rowlinson

Lawrence Mark Gelbert

Angelina Vucic Ciaccia

David Thompson Berg

Bruce Molitoris

Peter Edward Vaillancourt

Rosamund Carol Smith

Yanwen Fu

Lihua Huang

John Mcneill McGill, Iii

David Eugene Joyce

Mohammed Amin Khan

Raheleh Toughiri

Linda Maureen O'Bryan

Linda O'Bryan (Nee Tobias)

Bruce A Molitoris

John Mcneill Mcgill

Brian William Grinnell

Linda O O'Bryan

Antibodies that bind SARS-CoV spike protein, SARS-CoV-2 spike protein, and methods of using same for treating or preventing conditions associated with SARS or COVID-19 and for detecting SARS-CoV or SARS-CoV-2.

Anti-coronavirus antibodies and methods of use

Antibodies that bind SARS-CoV Spike protein, SARS-CoV-2 Spike protein, and methods of using same for treating or preventing conditions associated with SARS or COVID-19 and for detecting SARS-CoV or SARS-CoV-2.

There is disclosed a process for forming chemically-locked bispecific or heterodimer antibodies, preferably in the IgG class, in high specificity and with high homogeneity. More specifically, there is disclosed a chemically-locked bispecific IgG class antibody having a linkage region joined together with bio-orthogonal click chemistry.

Chemically-locked bispecific antibodies

The invention relates to formulations that demonstrate the feasibility of oral absorption comprising glucose-like peptide-1 compounds and specified delivery agents, and to methods of stimulating GLP-1 receptor in a subject in need of such stimulation, by administration of the formulation of the present invention.

Formulation comprising GLP-1

The present invention provides a method for preventing and/or treating subjects with acute renal failure caused by a variety of conditions. The method comprises administering to the subject soluble thrombomodulin which does not activate Protein C. In conjunction with standard of care, soluble thrombomodulin that does not activate Protein C will prevent or reduce acute kidney injury and subsequent morbidity and mortality.

Treating acute renal failure with soluble thrombomodulin variants

Anti-myostatin antibodies are identified that are characterized as having high affinity and may be chimeric, humanized or fully human antibodies, immunoconjugates of the antibodies or antigen-binding fragments thereof. The antibodies of the invention are useful for increasing muscle mass, increasing bond density, or for the treatment of various disorders in mammalian and avian species, X17251.

Anti-myostatin antibodies

Method for administering GLP-1 molecules

The present invention provides very high affinity antibodies, or antigen-binding fragments thereof, that neutralize mature human TGF-&#x3b2;1, TGF-&#x3b2;2, and TGF-&#x3b2;3. The antibodies of the invention are useful for treating cell proliferative disorders in a mammal.

TGF-beta binding antibodies

Method of treating a disease or pathological condition with activated protein C or a compound having activated protein C activity by direct regulation of the expression of specific genes associated with the disease or pathological condition.

Methods of treating diseases with activated protein C

Anti-myostatin antibodies are identified that are characterized as having high affinity and may be chimeric, humanized or fully human antibodies, immunoconjugates of the antibodies or antigen-binding fragments thereof. The antibodies of the invention are useful for increasing muscle mass, increasing bone density, or for the treatment of various disorders in mammalian and avian species.

TGF-&#x3b2; binding antibodies

Novel protein C derivatives are described. These polypeptides retain the biological activity of the wild-type human protein C with substantially longer half-lives in human blood. These polypeptides will require either less frequent administration and/or smaller dosage than wild-type human protein C in the treatment of vascular occlusive disorders, hypercoagulable states, thrombotic disorders and disease states predisposing to thrombosis.

Protein C derivatives

Novel human protein C derivatives are described. These derivatives have increased anti-coagulation activity and resistance to inactivation by serpins, compared to wild-type protein C and retain the biological activity of the wild-type human protein D. These derivatives will require either less frequent administration and/or smaller dosage than wild-type human protein C in the treatment of acute coronary syndromes, vascular occlusive disorders, hyper coagulable states, thrombotic disorders and disease states predisposing to thrombosis.

Growing community of inventors

Carmel, IN, United States of America

Bryan Edward Jones